Membranous glomerulopathy

2007 ◽  
pp. 55-79
Author(s):  
C. D. Short
Keyword(s):  
Membranous Glomerulopathy

scholarly journals NELL1-associated Membranous Glomerulopathy Following Hematopoeitic Stem Cell Transplantation

2021 ◽  
Author(s):  
Satoru Kudose ◽  
Miroslav Sekulic ◽  
Collette J. Mehring ◽  
Dominick Santoriello ◽  
Ibrahim Batal ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Membranous Glomerulopathy

20: A Rare Case of Interstitial Nephritis With Secondary Membranous Glomerulopathy Due to Glimepiride

2010 ◽  
Vol 55 (4) ◽  
pp. B36
Author(s):  
Sana Akbar ◽  
Melvin Goldblat ◽  
Sadanand Palekar ◽  
Sachin Sachdev ◽  
Adeem Akbar
Keyword(s):  
Interstitial Nephritis ◽  
Rare Case ◽  
Membranous Glomerulopathy

Treatment of Idiopathic Membranous Glomerulopathy

Proteinuria ◽  
1985 ◽  
pp. 175-193
Author(s):  
Jerome G. Porush ◽  
Pierre F. Faubert
Keyword(s):  
Membranous Glomerulopathy

scholarly journals New Aspects of Pathogenesis and Treatment of Membranous Glomerulopathy After the MENTOR Study

2020 ◽  
pp. 46-53
Author(s):  
Maurizio Salvadori ◽  
Aris Tsalouchos
Keyword(s):  
Nephrotic Syndrome ◽  
Adrenocorticotropic Hormone ◽  
Glomerular Diseases ◽  
The Past ◽  
Superior Efficacy ◽  
Novel Drugs ◽  
Membranous Glomerulopathy ◽  
Blocking Mechanisms ◽  
Antigenic Epitopes

Membranous nephropathy (MN) is the major cause of nephrotic syndrome in adults, accounting for 20% of cases with an annual incidence of 1 per 100,000 population. In the past 10 years, the role of podocytes has been identified. Environmental triggers in genetically predisposed patients can activate podocytes to exhibit antigenic epitopes, including PLA2R, THBS1, and NELL1, which become targets of specific autoantibodies with subsequent complement activation. The discovery of these mechanisms has opened a new horizon in the treatment of MN, and novel drugs are available with more specific mechanisms of action. Rituximab, a monoclonal antibody directed against CD20 expressed on B lymphocytes, has been used in several trials and appears to induce remission of nephrotic syndrome in 60% of patients (GEMRITUX trial). The recently published results of the MENTOR trial documented the superior efficacy of rituximab in patients observed for up to 24 months. In MN, the concept of targeting disease control has introduced novel therapies with specific blocking mechanisms, such as belimumab; nonspecific blocking mechanisms, such as those against adrenocorticotropic hormone; and new therapeutic options, such as ofatumumab, bortezomib, and eculizumab, which have recognised the pathological processes involved in the glomerular diseases.

Idiopathic membranous glomerulopathy

1992 ◽  
pp. 25-27
Author(s):  
A. Meyrier ◽  
P. Niaudet ◽  
J. Brodehl
Keyword(s):  
Membranous Glomerulopathy

scholarly journals Steroids and Cytotoxic Drugs in the Treatment of Membranous Glomerulopathy

Nephron ◽  
1988 ◽  
Vol 50 (3) ◽  
pp. 263-264 ◽  
Author(s):  
Silvio Garattini ◽  
Tullio Bertani ◽  
Giuseppe Remuzzi
Keyword(s):  
Cytotoxic Drugs ◽  
Membranous Glomerulopathy

scholarly journals A Case of Concurrent MPO-/PR3-Negative ANCA-Associated Glomerulonephritis and Membranous Glomerulopathy

2015 ◽  
Vol 2015 ◽  
pp. 1-5
Author(s):  
Yasuyuki Nakada ◽  
Nobuo Tsuboi ◽  
Yasuto Takahashi ◽  
Hiraku Yoshida ◽  
Yoriko Hara ◽  
...  
Keyword(s):  
Renal Biopsy ◽  
Indirect Immunofluorescence ◽  
Crescentic Glomerulonephritis ◽  
Antineutrophil Cytoplasmic Antibody ◽  
Basement Membranes ◽  
Proteinase 3 ◽  
Renal Deterioration ◽  
Membranous Glomerulopathy ◽  
Immunosorbent Assays ◽  
The Relationship

We report a case in which antineutrophil cytoplasmic antibody- (ANCA-) associated glomerulonephritis and membranous glomerulopathy (MGN) were detected concurrently. The patient showed rapidly progressive renal deterioration. A renal biopsy showed crescentic glomerulonephritis, together with marked thickening and spike and bubbling formations in the glomerular basement membranes. Indirect immunofluorescence examination of the patient’s neutrophils showed a perinuclear pattern. Enzyme-linked immunosorbent assays revealed that the ANCA in this case did not target myeloperoxidase (MPO) or proteinase 3 (PR3) but bactericidal-/permeability-increasing protein, elastase, and lysosome. The relationship between these two etiologically distinct entities, MPO-/PR3-negative ANCA-associated glomerulonephritis and MGN, remains unclear.

Renal pathology

2017 ◽  
Author(s):  
James Carton
Keyword(s):  
Kidney Disease ◽  
Basement Membrane ◽  
Reflux Nephropathy ◽  
Kidney Injury ◽  
Renal Pathology ◽  
Renal Diseases ◽  
Obstructive Nephropathy ◽  
Hypertensive Nephropathy ◽  
Membranous Glomerulopathy ◽  
Post Infectious

This chapter discusses renal pathology, including acute kidney injury (AKI), chronic kidney disease (CKD), nephrotic syndrome, hereditary renal diseases, Alport’s syndrome and thin basement membrane lesion, hypertensive nephropathy, diabetic nephropathy, minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous glomerulopathy, glomerulonephritis, IgA nephropathy, post-infectious glomerulonephritis, C3 glomerulopathy, anti-glomerular basement membrane disease, monoclonal gammopathy-associated kidney disease, acute tubular injury, acute tubulointerstitial nephritis, reflux nephropathy, and obstructive nephropathy.

Sign in / Sign up

Export Citation Format

Share Document